KLK3 and prostate cancer: Systemic administration of this compound at a dose of 10 mg/kg for three cycles of five consecutive days in nude mice with human prostate cancer xenografts showed minimal effect on tumor growth but led to significant reduction in serum KLK3 levels [130].